about
Addition of N-terminal pro-B-type natriuretic peptide levels to electrocardiography criteria for detection of left ventricular hypertrophy: the ARIRANG study.Prognostic value of short-term follow-up BNP in hospitalized patients with heart failure.Korean Guidelines for Diagnosis and Management of Chronic Heart Failure.Relation of Renal Function with Left Ventricular Systolic Function and NT-proBNP Level and Its Prognostic Implication in Heart Failure with Preserved versus Reduced Ejection Fraction: an analysis from the Korean Heart Failure (KorHF) Registry.Is There a Sex-Related Difference in the Obesity Paradox in Systolic Heart Failure? Sex-Related Difference in the Obesity Paradox.Impact of Heart Rate Reduction with Maximal Tolerable Dose of Bisoprolol on Left Ventricular Reverse Remodeling.Prognostic Significance of Left Axis Deviation in Acute Heart Failure Patients with Left Bundle branch block: an Analysis from the Korean Acute Heart Failure (KorAHF) RegistryValidation of the MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) heart failure risk score and the effect of adding natriuretic peptide for predicting mortality after discharge in hospitalized patients with heart failureKSHF Guidelines for the Management of Acute Heart Failure: Part II. Treatment of Acute Heart FailureKSHF Guidelines for the Management of Acute Heart Failure: Part I. Definition, Epidemiology and Diagnosis of Acute Heart FailureKSHF Guidelines for the Management of Acute Heart Failure: Part III. Specific Management of Acute Heart Failure According to the Etiology and Co-morbidityPrognostic Effect of Guideline-Directed Therapy Is More Noticeable Early in the Course of Heart FailureBeta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction: Results from The Korea Acute Heart Failure (KorAHF) Registry.Artificial intelligence algorithm for predicting mortality of patients with acute heart failurePrognostic Implication of Ventricular Conduction Disturbance Pattern in Hospitalized Patients with Acute Heart Failure SyndromeGuideline-directed therapy at discharge in patients with heart failure and atrial fibrillation
P50
Q35198554-D0CB7439-81EB-4B4D-A05A-5A418160CCC0Q38642916-5529C94A-837E-4C52-9FB9-5D0C35866B4EQ41686228-76D8A67C-92B0-482B-8645-1E9B9E781B64Q41686272-C8F623B1-4A22-42D7-8D7F-D0A8F8C71EB5Q47142903-ACFC719D-8639-4B34-B360-C2912C8AAF29Q55309021-0C202B33-86B8-422A-A6AA-1640182BA2F0Q58565077-EE4749F0-C225-43C3-ABEC-51D31DE43B18Q60049738-77A3D414-8994-45FB-8A92-0DF6CE8B71DAQ60931782-2947DB86-1717-461B-9552-253B144DB975Q60931790-492BD5C8-7667-4755-8F1F-D23EA9F06369Q60935054-C905BF6F-15A3-4190-A906-57FBAC263A7FQ64094704-A166E4B5-2066-4F25-B380-11421423B48CQ64930053-632E33A7-0FDB-47E7-A55B-60AEF6BA4D77Q91709787-8D5842C5-EB64-46CE-8808-5DFA4C354854Q92496019-0958C2DD-EE3A-48D1-B99A-B8B25745A192Q93160912-D752531F-80C2-498A-9D7B-5248B82E0DE9
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Byung-Su Yoo
@en
Byung-Su Yoo
@nl
type
label
Byung-Su Yoo
@en
Byung-Su Yoo
@nl
prefLabel
Byung-Su Yoo
@en
Byung-Su Yoo
@nl
P31
P496
0000-0002-3395-4279